Amalgamated Financial’s Stoke Therapeutics STOK Stock Holding History

Amalgamated Financial’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$66K	Buy	+3,118	New	+$62.4K	﹤0.01%	2287

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amalgamated Financial's STOK Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Stoke Therapeutics (STOK) in Q1 2022: 3,118 shares worth $66K. The stake represents ﹤0.01% of the portfolio and ranks #2287 among its holdings.

99 funds tracked by Wall St. Rank hold STOK as of Q1 2022.

Amalgamated Financial held 3,118 shares of Stoke Therapeutics worth $66K as of Q1 2022.
Stoke Therapeutics was a new Amalgamated Financial position in Q1 2022.
Stoke Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2287 holding.
99 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.